SCINTIX® technology is a novel therapy for patients with tumors in the lung or bone arising from primary and metastatic cancer. This breakthrough technology uses live, continuously updated data throughout the entire treatment session to determine where to deliver radiotherapy.
DOWNLOAD WHITEPAPER
SCINTIX therapy is the only theranostic approach to external-beam radiotherapy that leverages emissions from radiotracers to treat cancer using the individual molecular characteristics of each tumor on the day of treatment.
The X1 platform with SCINTIX therapy can treat multiple tumors in the lung or bone in a single plan with conformal dose delivery and potentially smaller margins, resulting in less toxicity that should improve patient outcomes.
When the tumor moves, the dose moves too. Our SCINTIX technology tracks and shifts the dose in response to both periodic and non-periodic tumor motion caused by physiologic processes, and unexpected motion, like surprise shifts in patient position.
SCINTIX therapy is the only theranostic approach to external-beam radiotherapy that leverages emissions from radiotracers to treat cancer using the individual molecular characteristics of each tumor on the day of treatment.
The X1 platform with SCINTIX therapy can treat multiple tumors in the lung or bone in a single plan with conformal dose delivery and potentially smaller margins, resulting in less toxicity that should improve patient outcomes.
When the tumor moves, the dose moves too. Our SCINTIX technology tracks and shifts the dose in response to both periodic and non-periodic tumor motion caused by physiologic processes, and unexpected motion, like surprise shifts in patient position.
The X1 platform with SCINTIX therapy treats multiple tumors in a single treatment plan. Hybrid treatments include both SCINTIX and SBRT targets in a single session so clinicians can choose the best therapy for each tumor.
SCINTIX therapy and the X1 platform enable clinicians to treat multiple tumors in a single plan.
By combining radiotherapy and PET-CT in a novel way,
we can find and treat cancer using its own emissions.
Learn more about SCINTIX biology-guided radiotherapy and RefleXion’s vision.
See how SCINTIX therapy expands radiotherapy to metastatic patients.
Take a deeper dive into the RefleXion X1 platform.
SCINTIX therapy uses PET – the gold standard in cancer imaging – in a new way to solve the conundrum of targeting and motion management. A single radiopharmaceutical injection turns each cancer into a biological beacon that communicates data about its location, via a continuous stream of emissions. Onboard PET detectors on the X1 machine sense the emissions and use this data to direct treatment delivery with sub-second latency. The intrafraction PET data display provides added confidence for clinicians that the dose is being delivered as planned.
Watch Video
For cancer patients with metastatic disease, the X1 platform enables clinicians to treat multiple tumors in a single plan, optimizing dose for all targets and organs-at-risk simultaneously. Hybrid treatments, combining SCINTIX and SBRT targets, give clinicians the flexibility to choose the best therapy for each target and deliver that in the same session. By using a tracked dose delivery, the PTV may be more conformal to spare healthy tissue and preserve dose for additional tumors. Together, these capabilities bring the cost effectiveness and efficacy of radiotherapy to more advanced stage patients.
WATCH VIDEO
SCINTIX therapy elevates the performance of radiopharmaceuticals from a diagnostic tool to one that precisely controls treatment delivery, creating a new theranostic approach to external-beam radiotherapy. Currently cleared for use with FDG, RefleXion has forged collaboration and licensing agreements with industry-leading radiopharmaceutical manufacturers to develop PSMA tracers for prostate cancer, and FAP for treating cancers with a high unmet need.
WATCH VIDEO
The RefleXion X1 with SCINTIX therapy is the only hybrid platform offering both biologic technology for tumors in motion and anatomic capabilities via its onboard fan-beam kVCT. The X1 fits in most standard vaults without the need for additional shielding or expensive construction.
WATCH VIDEO
A closer look at the proprietary technologies that combine to create our game-changing approach to cancer treatment.
See how SCINTIX therapy combines PET and CT with radiotherapy in a novel way.
View our latest peer-reviewed articles and abstracts.
Learn more about our PREMIER registry for patients with all stages of cancer.
See how SCINTIX therapy combines PET and CT with radiotherapy in a novel way.
View our latest peer-reviewed articles and abstracts.
Learn more about our PREMIER registry for patients with all stages of cancer.
Let us tell you more.
Contact UsStay up to date.
Sign Up